GlaxoSmithKline GSK
$50.33 −$0.08 (-0.16%)
Market closed · Nov 7, 9:10 am ET · Last extended-hours $50.33 0.00%
Open$49.07
Prev close$50.41
Day range$48.94 – $50.74
Volume3.19M
Market cap$100.88B
P/E (TTM)17.5
Dividend yield3.56%
Earnings
Average move on report day±3.5%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+8.2%
Worst reaction-5.6%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 28 Oct 2026 | Pre Market | ±3.7% | -4.32% | Bigger than priced |
| 2026/Q2 | 28 Jul 2026 | Pre Market | ±3.7% | +3.33% | Within range |
| 2026/Q1 | 29 Apr 2026 | None | ±3.0% | -5.64% | Bigger than priced |
| 2025/Q4 | 4 Feb 2026 | None | ±6.0% | +7.29% | Bigger than priced |
| 2025/Q3 | 29 Oct 2025 | None | ±3.9% | +5.10% | Bigger than priced |
| 2025/Q2 | 30 Jul 2025 | Pre Market | ±4.4% | +3.45% | Within range |
| 2025/Q1 | 30 Apr 2025 | None | ±4.0% | +2.26% | Within range |
| 2024/Q4 | 5 Feb 2025 | None | ±4.7% | +8.21% | Bigger than priced |
| 2024/Q3 | 30 Oct 2024 | Pre Market | ±5.8% | -3.04% | Within range |
| 2024/Q2 | 31 Jul 2024 | None | ±5.6% | -2.51% | Within range |
| 2024/Q1 | 1 May 2024 | None | ±4.9% | +2.73% | Within range |
| 2023/Q3 | 1 Nov 2023 | Pre Market | ±3.9% | -3.14% | Within range |
| 2023/Q2 | 26 Jul 2023 | None | ±3.9% | +0.48% | Within range |
| 2023/Q1 | 26 Apr 2023 | None | ±3.1% | -2.66% | Within range |
| 2022/Q4 | 1 Feb 2023 | None | ±4.0% | +0.65% | Within range |
| 2022/Q3 | 2 Nov 2022 | None | ±3.2% | -1.02% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026 · reported in GBP
Revenue£8.89B+4.0% YoY
Operating profit£2.13B-18.0% YoY
Net profit£1.70B-20.6% YoY
Diluted EPS£0.76-22.8% YoY
Free cash flow£2.28B+69.5% YoY
Operating cash flow£2.81B
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin72.6%
Operating margin19.1%
Net margin13.0%
Return on equity24.9%
Return on assets6.5%
Return on invested capital13.1%
Current ratio0.86
Liabilities / assets74.4%
Cash & investments£2.96B
Total debt£21.70B
Net cash (debt)-£18.74B
Free cash flow / sales18.7%
No comments yet — be the first to weigh in on GSK.
Sign in to join the discussion.